Croda International Plc Company Overview
Croda International Plc is a UK-headquartered specialty ingredients company based at Cowick Hall in Snaith, East Yorkshire. Founded in Yorkshire in 1925, Croda develops high-performance ingredients and formulation technologies principally for consumer care and life-science applications. Its portfolio includes emollients, emulsifiers, surfactants, rheology modifiers, active cosmetic ingredients, botanical extracts, fragrances and flavours, pharmaceutical excipients, vaccine adjuvants, lipid delivery systems, crop-protection formulation aids and seed-enhancement technologies. These materials serve beauty and personal care, home care, pharmaceuticals, vaccines, agriculture and selected industrial applications. Croda generated £1.699 billion of sales in 2025, with Consumer Care and Life Sciences accounting for the large majority of revenue.
Croda's strategic positioning has shifted substantially toward markets where ingredient functionality, formulation know-how and customer co-development create higher barriers to substitution. Consumer Care combines beauty, home-care and fragrance capabilities, while Life Sciences concentrates on pharmaceutical delivery, crop protection and seed technologies. Industrial Specialties has a different role, utilizing chemistry and capacity at shared manufacturing plants rather than acting as a primary strategic growth platform. Recent capital deployment has therefore focused on extracting returns from investments in pharmaceutical lipids, biologics delivery, fragrances and flavours, biotechnology-derived beauty ingredients and Asian manufacturing capacity rather than rebuilding a broad industrial chemicals portfolio.
Croda International Plc Company Snapshot
|
Parameter |
Information |
|---|---|
|
Company Name |
Croda International Plc |
|
Headquarters / Registered Office |
Cowick Hall, Snaith, East Yorkshire, United Kingdom |
|
Founded |
1925 |
|
Group Chief Executive |
Steve Foots, CBE |
|
Ownership |
Publicly traded company |
|
Primary Listing |
London Stock Exchange |
|
Ticker |
CRDA |
|
FY2025 Revenue |
£1.699 billion |
|
FY2025 Adjusted Operating Profit |
£295.3 million |
|
FY2025 Adjusted Operating Margin |
17.4% |
|
Employees |
More than 5,800 |
|
Global Presence |
94 locations across 36 countries |
|
Operating Businesses |
Consumer Care; Life Sciences; Industrial Specialties |
Steve Foots remains Croda's Group Chief Executive, a position he has held since 2012. The company reported FY2025 sales of £1.699 billion and adjusted operating profit of £295.3 million, with an adjusted operating margin of 17.4%. Croda's latest corporate disclosures describe a workforce of more than 5,800 employees across 94 locations in 36 countries.
Croda International Plc Business Structure and Competitive Position
Croda operates through Consumer Care, Life Sciences and Industrial Specialties, but these businesses serve different strategic functions. Consumer Care contains Beauty Care, Beauty Actives, Fragrances & Flavours and Home Care, combining formulation ingredients with active and sensory technologies. Life Sciences encompasses Pharma, Crop Protection and Seed Enhancement, where regulatory requirements and technical validation are more pronounced. Industrial Specialties uses chemistry and available capacity at shared manufacturing sites to supply selected niche industrial applications and co-stream products. This structure allows Croda to prioritize innovation and customer-facing resources in Consumer Care and Life Sciences while using Industrial Specialties to improve utilization and economics across shared production infrastructure.
Croda's competitive position is based on the functional importance of its ingredients within customer formulations. In beauty and home care, performance depends on ingredient interaction, sensory characteristics, stability and formulation compatibility. Pharma requires high purity, controlled manufacturing and extensive regulatory and technical qualification, particularly for excipients, vaccine adjuvants and nucleic-acid delivery systems. Crop Protection and Seed Enhancement depend on delivery efficiency, coating technology and agronomic performance. Croda's research model therefore combines chemistry, biotechnology and application science with close customer development. The company reported that it retained approximately 90% of larger customers between 2019 and 2024 despite significant market volatility, illustrating the value of embedded formulation relationships.
Croda International Plc Business Segments and Revenue Analysis
Croda reports sales and adjusted operating profit by its three operating businesses rather than EBITDA by segment. Accordingly, adjusted operating profit is the most appropriate officially disclosed segment earnings measure.
|
Business Segment |
FY2025 Sales |
FY2025 Adjusted Operating Profit |
Principal Activities |
|---|---|---|---|
|
Consumer Care |
£972.7 million |
£169.8 million |
Beauty Care, Beauty Actives, Fragrances & Flavours, Home Care |
|
Life Sciences |
£532.2 million |
£116.5 million |
Pharma, Crop Protection, Seed Enhancement |
|
Industrial Specialties |
£194.5 million |
£9.0 million |
Specialty industrial applications and shared-site capacity utilization |
FY2025 Consumer Care sales increased 5.7%, while Life Sciences grew 5.5%; Industrial Specialties sales declined 4.6%.
Consumer Care
Consumer Care is Croda's largest business and combines Beauty Care, Beauty Actives, Fragrances & Flavours, and Home Care. Beauty Care supplies functional ingredients used to control texture, stability, conditioning and sensory performance, while Beauty Actives includes scientifically supported active ingredients and botanical or biotechnology-derived solutions. Fragrances & Flavours includes Iberchem and Parfex capabilities, extending Croda into sensory formulation. Home Care supplies ingredients for household and institutional cleaning applications. Competitive differentiation comes from formulation knowledge, application laboratories, biotechnology capabilities and close collaboration with consumer-product manufacturers. Consumer Care generated £972.7 million of sales and £169.8 million of adjusted operating profit in 2025.
Life Sciences
Life Sciences comprises Pharma, Crop Protection and Seed Enhancement. Pharma supplies specialty excipients, vaccine adjuvants and lipid technologies supporting small-molecule medicines, biologics and nucleic-acid delivery. Crop Protection develops surfactants and formulation technologies that improve the delivery and performance of agricultural active ingredients, while Seed Enhancement provides coatings and services used to improve seed handling and biological performance. These markets typically involve longer development and qualification cycles than consumer formulations, particularly in pharmaceutical applications. Croda differentiates through high-purity manufacturing, formulation science and acquired technology platforms including Avanti Polar Lipids. FY2025 Life Sciences sales reached £532.2 million and adjusted operating profit increased to £116.5 million.
Industrial Specialties
Industrial Specialties has a distinct role within Croda's manufacturing model. Rather than serving as a principal investment platform, it generates additional value from shared manufacturing sites by using existing chemistry, co-streams and available capacity to supply niche industrial markets. Applications can include lubricants, coatings, polymers, process chemicals and other performance-oriented industrial formulations. Croda explicitly describes the business as contributing to manufacturing efficiency by improving utilization of shared sites and monetizing core chemistries outside Consumer Care and Life Sciences. FY2025 sales were £194.5 million, while adjusted operating profit was £9.0 million. The comparatively lower profitability reflects the segment's capacity-utilization role and greater exposure to product-mix variability.
Croda International Plc Global Manufacturing and Geographic Footprint
Croda operates a geographically distributed network of manufacturing, innovation and commercial locations across Europe, the Americas and Asia-Pacific. The United Kingdom remains an important manufacturing and technology base, with facilities including Rawcliffe Bridge, Ditton, Leek and other locations supporting specialty ingredients and pharmaceutical technologies. Cowick Hall in East Yorkshire serves as the corporate headquarters.
North America is strategically important for pharmaceutical delivery and other specialty ingredients. Croda's acquisition of Avanti Polar Lipids added lipid research and manufacturing capabilities centered in Alabama, strengthening exposure to drug-development and nucleic-acid delivery markets. The company has invested in additional pharmaceutical manufacturing capacity in the United States and United Kingdom through a multi-year program totaling approximately £175 million, supported in part by government co-investment.
Asia has become increasingly important to Croda's growth model. The company has developed a new surfactants facility at Dahej, India, and invested in a combined Beauty Actives and Fragrances & Flavours manufacturing platform in Guangzhou, China. It has also established nucleic-acid delivery application capabilities in Singapore. These regional assets support a broader localization strategy: high-value ingredients still rely on global technology platforms, but customer development and manufacturing proximity matter for beauty formulations, consumer products, agriculture and pharmaceutical development. Croda's shared-site model additionally allows multiple businesses to use common chemical infrastructure, creating utilization benefits where manufacturing chemistries overlap.
Croda International Plc Mergers, Divestitures and Portfolio Transformation
Croda's recent portfolio strategy has emphasized extracting returns from earlier acquisitions and major capital investments rather than pursuing large new transactions. The company's transformation accelerated after the 2022 disposal of the majority of its Performance Technologies and Industrial Chemicals businesses, which shifted its center of gravity toward Consumer Care and Life Sciences. Subsequent investments have concentrated on the platforms acquired through Iberchem, Avanti Polar Lipids and Solus Biotech. Croda reported strong 2025 growth from these acquired technologies, including double-digit performance in fragrances and flavours, drug-research lipids and biotechnology-derived ceramides.
Solus Biotech, acquired in 2023, strengthened Croda's beauty-actives portfolio through biotechnology-derived ceramides and other ingredients. Croda has since focused on globalizing the acquired technology and extending ceramide applications beyond skin care into scalp and hair formulations. In Pharma, investment following the Avanti acquisition has expanded lipid and drug-delivery capabilities, while the broader £175 million manufacturing program has increased capacity for pharmaceutical materials in the United States and United Kingdom.
The operating focus shifted further in 2025–2026 toward productivity and return improvement. Croda is rationalizing processes and headcount across 11 shared manufacturing sites, optimizing its end-to-end supply chain, globalizing procurement and reducing product complexity. Management has also indicated that near-term acquisitions are likely to be limited to complementary next-generation technologies or partnerships. This represents the next stage of Croda's portfolio transition: after substantial acquisition and capacity investment, the emphasis has moved from portfolio construction toward utilization, commercialization and margin recovery.
Related USDAnalytics Market Research
Examines differentiated surfactant chemistries used across personal care, home care, industrial formulations and other applications requiring controlled wetting, emulsification, dispersion and cleansing performance.
Examines non-ionic surfactants used in personal care, household cleaning, agriculture and industrial formulations for emulsification, detergency, wetting, solubilization and formulation stability.
Examines amino-acid-derived surfactants used primarily in personal-care and cleansing formulations requiring mildness, biodegradability, foaming, detergency and compatibility with skin and hair applications.
Examines emulsifying ingredients used to stabilize oil-and-water systems across personal care, pharmaceuticals, food, agriculture and other formulated products requiring consistent dispersion and texture.
Examines natural and synthetic fragrance ingredients used in fine fragrances, personal care, cosmetics, home care and consumer products to create and modify scent profiles.
Flavors and Fragrances Chemicals Market
Examines aroma and flavor chemicals used in fragrances, foods, beverages, personal care and household products to deliver distinctive sensory, taste and olfactory characteristics.